{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:30:25Z","timestamp":1782473425470,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["Research Grant"],"award-info":[{"award-number":["Research Grant"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11064-018-2514-y","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T02:28:19Z","timestamp":1521772099000},"page":"1035-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-5714","authenticated-orcid":false,"given":"Adrian","family":"Newman-Tancredi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"issue":"Suppl 1","key":"2514_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jnc.13750","volume":"139","author":"W Oertel","year":"2016","unstructured":"Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem 139(Suppl 1):325\u2013337","journal-title":"J Neurochem"},{"key":"2514_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","volume":"76","author":"D Vijayakumar","year":"2016","unstructured":"Vijayakumar D, Jankovic J (2016) Drug-induced dyskinesia, Part 1: treatment of levodopa-induced dyskinesia. Drugs 76:759\u2013777","journal-title":"Drugs"},{"key":"2514_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fneur.2014.00242","volume":"5","author":"AM Cenci","year":"2014","unstructured":"Cenci AM (2014) Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 5:242","journal-title":"Front Neurol"},{"key":"2514_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.biopha.2015.01.029","volume":"70","author":"S Sharma","year":"2015","unstructured":"Sharma S, Singh S, Sharma V, Singh VP, Deshmukh R (2015) Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies. Biomed Pharmacother 70:283\u2013293","journal-title":"Biomed Pharmacother"},{"key":"2514_CR5","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain 136:2419\u20132431","journal-title":"Brain"},{"key":"2514_CR6","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1093\/brain\/awh290","volume":"127","author":"R Fuente-Fernandez de la","year":"2004","unstructured":"de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain 127:2747\u20132754","journal-title":"Brain"},{"key":"2514_CR7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1093\/brain\/awn085","volume":"131","author":"J Lee","year":"2008","unstructured":"Lee J, Zhu WM, Stanic D, Finkelstein DI, Horne MH, Henderson J, Lawrence AJ, O\u2019Connor L, Tomas D, Drago J, Horne MK (2008) Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 131:1574\u20131587","journal-title":"Brain"},{"key":"2514_CR8","first-page":"120","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain 131:120\u2013131","journal-title":"Brain"},{"key":"2514_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ana.22097","volume":"68","author":"D Rylander","year":"2010","unstructured":"Rylander D, Parent M, O\u2019Sullivan SS, Dovero S, Lees AJ, Bezard E, Descarries L, Cenci MA (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68:619\u2013628","journal-title":"Ann Neurol"},{"key":"2514_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jocn.2011.09.008","volume":"19","author":"PA Cheshire","year":"2012","unstructured":"Cheshire PA, Williams DR (2012) Serotonergic involvement in levodopa-induced dyskinesias in Parkinson\u2019s disease. J Clin Neurosci 19:343\u2013348","journal-title":"J Clin Neurosci"},{"key":"2514_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mds.26144","volume":"30","author":"P Cheshire","year":"2015","unstructured":"Cheshire P, Ayton S, Bertram KL, Ling H, Li A, McLean C, Halliday GM, O\u2019Sullivan SS, Revesz T, Finkelstein DI, Storey E, Williams DR (2015) Serotonergic markers in Parkinson\u2019s disease and levodopa-induced dyskinesias. Mov Disord 30:796\u2013804","journal-title":"Mov Disord"},{"key":"2514_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1212\/WNL.0000000000001909","volume":"85","author":"JY Lee","year":"2015","unstructured":"Lee JY, Seo S, Lee JS, Kim HJ, Kim YK, Jeon BS (2015) Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology 85:853\u2013860","journal-title":"Neurology"},{"key":"2514_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1823-7","author":"G Pagano","year":"2017","unstructured":"Pagano G, Niccolini F, Politis M (2017) The serotonergic system in Parkinson\u2019s patients with dyskinesia: evidence from imaging studies. J Neural Transm. \n                    https:\/\/doi.org\/10.1007\/s00702-017-1823-7","journal-title":"J Neural Transm"},{"key":"2514_CR14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1212\/WNL.0000000000002494","volume":"86","author":"AA Roussakis","year":"2016","unstructured":"Roussakis AA, Politis M, Towey D, Piccini P (2016) Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias. Neurology 86:1152\u20131158","journal-title":"Neurology"},{"key":"2514_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fneur.2014.00078","volume":"5","author":"M Carta","year":"2014","unstructured":"Carta M, Tronci E (2014) Serotonin system implication in l-DOPA-induced dyskinesia: from animal models to clinical investigations. Front Neurol 5:78","journal-title":"Front Neurol"},{"key":"2514_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1837-1","author":"K Lanza","year":"2018","unstructured":"Lanza K, Bishop C (2018) Serotonergic targets for the treatment of l-DOPA-induced dyskinesia. J Neural Transm. \n                    https:\/\/doi.org\/10.1007\/s00702-017-1837-1","journal-title":"J Neural Transm"},{"key":"2514_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1021\/acschemneuro.5b00034","volume":"6","author":"R Andrade","year":"2015","unstructured":"Andrade R, Huereca D, Lyons JG, Andrade EM, McGregor KM (2015) 5-HT1A receptor-mediated autoinhibition and the control of serotonergic cell firing. ACS Chem Neurosci 6:1110\u20131115","journal-title":"ACS Chem Neurosci"},{"key":"2514_CR18","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829\u20131834","journal-title":"Neurology"},{"key":"2514_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","volume":"87","author":"KL Eskow","year":"2007","unstructured":"Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 87:306\u2013314","journal-title":"Pharmacol Biochem Behav"},{"key":"2514_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00221-013-3621-2","volume":"230","author":"P Huot","year":"2013","unstructured":"Huot P, Fox SH (2013) The serotonergic system in motor and non-motor manifestations of Parkinson\u2019s disease. Exp Brain Res 230:463\u2013476","journal-title":"Exp Brain Res"},{"key":"2514_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.111.184093","volume":"339","author":"P Huot","year":"2011","unstructured":"Huot P, Fox SH, Newman-Tancredi A, Brotchie JM (2011) Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson\u2019s disease: an approach to reducing dyskinesia without exacerbating parkinsonism? J Pharmacol Exp Ther 339:2\u20138","journal-title":"J Pharmacol Exp Ther"},{"key":"2514_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuropharm.2015.05.033","volume":"97","author":"P Huot","year":"2015","unstructured":"Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM (2015) The highly-selective 5-HT agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology 97:306\u2013311","journal-title":"Neuropharmacology"},{"key":"2514_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","volume":"93","author":"H Iderberg","year":"2015","unstructured":"Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A (2015) Activity of serotonin 5-HT1A receptor \u2018biased agonists\u2019 in rat models of Parkinson\u2019s disease and l-DOPA-induced dyskinesia. Neuropharmacology 93:52\u201367","journal-title":"Neuropharmacology"},{"key":"2514_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","volume":"271","author":"H Iderberg","year":"2015","unstructured":"Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoort\u00e8re R, Cenci MA, Newman-Tancredi A (2015) NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat. Exp Neurol 271:335\u2013350","journal-title":"Exp Neurol"},{"key":"2514_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.expneurol.2017.03.013","volume":"292","author":"SM Meadows","year":"2017","unstructured":"Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C (2017) Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia. Exp Neurol 292:168\u2013178","journal-title":"Exp Neurol"},{"key":"2514_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.neuropharm.2016.01.013","volume":"105","author":"AC McCreary","year":"2016","unstructured":"McCreary AC, Varney MA, Newman-Tancredi A (2016) The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements. Neuropharmacology 105:651\u2013660","journal-title":"Neuropharmacology"},{"key":"2514_CR27","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","volume":"67","author":"N Pavese","year":"2006","unstructured":"Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67:1612\u20131617","journal-title":"Neurology"},{"key":"2514_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.bjp.0706859","volume":"149","author":"MB Assie","year":"2006","unstructured":"Assie MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A (2006) Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. Br J Pharmacol 149:170\u2013178","journal-title":"Br J Pharmacol"},{"key":"2514_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/npy.11.12","volume":"1","author":"A Newman-Tancredi","year":"2011","unstructured":"Newman-Tancredi A (2011) Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders. Neuropsychiatry 1:149\u2013164","journal-title":"Neuropsychiatry"},{"key":"2514_CR30","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/j.1476-5381.2010.00738.x","volume":"160","author":"L Llado-Pelfort","year":"2010","unstructured":"Llado-Pelfort L, Assie MB, Newman-Tancredi A, Artigas F, Celada P (2010) Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors. Br J Pharmacol 160:1929\u20131940","journal-title":"Br J Pharmacol"},{"key":"2514_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1476-5381.2008.00001.x","volume":"156","author":"A Newman-Tancredi","year":"2009","unstructured":"Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D (2009) Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol 156:338\u2013353","journal-title":"Br J Pharmacol"},{"key":"2514_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.expneurol.2011.07.006","volume":"231","author":"P Huot","year":"2011","unstructured":"Huot P, Brotchie JM (2011) 5-HT(1A) receptor stimulation and l-DOPA-induced dyskinesia in Parkinson\u2019s disease: bridging the gap between serotonergic and glutamatergic mechanisms. Exp Neurol 231:195\u2013198","journal-title":"Exp Neurol"},{"key":"2514_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","volume":"93C","author":"H Iderberg","year":"2015","unstructured":"Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A (2015) Activity of serotonin 5-HT receptor \u2018biased agonists\u2019 in rat models of Parkinson\u2019s disease and l-DOPA-induced dyskinesia. Neuropharmacology 93C:52\u201367","journal-title":"Neuropharmacology"},{"key":"2514_CR34","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"2007","unstructured":"Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. Academic Press, Cambridge"},{"key":"2514_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/0024-3205(76)90303-9","volume":"19","author":"BL Jacobs","year":"1976","unstructured":"Jacobs BL (1976) An animal behavior model for studying central serotonergic synapses. Life Sci 19:777\u2013785","journal-title":"Life Sci"},{"key":"2514_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0091-3057(93)90330-V","volume":"46","author":"NA Moore","year":"1993","unstructured":"Moore NA, Rees G, Sanger G, Perrett L (1993) 5-HT1A-mediated lower lip retraction: effects of 5-HT1A agonists and antagonists. Pharmacol Biochem Behav 46:141\u2013143","journal-title":"Pharmacol Biochem Behav"},{"key":"2514_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","volume":"10","author":"H Tanaka","year":"1999","unstructured":"Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10:631\u2013634","journal-title":"Neuroreport"},{"key":"2514_CR38","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07598.x","volume":"120","author":"A Nahimi","year":"2012","unstructured":"Nahimi A, Holtzermann M, Landau AM, Simonsen M, Jakobsen S, Alstrup AK, Vang K, Moller A, Wegener G, Gjedde A, Doudet DJ (2012) Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning. J Neurochem 120:806\u2013817","journal-title":"J Neurochem"},{"key":"2514_CR39","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819\u20131833","journal-title":"Brain"},{"key":"2514_CR40","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","volume":"76","author":"K Kannari","year":"2001","unstructured":"Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346\u20131353","journal-title":"J Neurochem"},{"key":"2514_CR41","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/syn.20630","volume":"63","author":"KL Eskow","year":"2009","unstructured":"Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of l-DOPA-induced dyskinesia in hemiparkinsonian rats. Synapse 63:610\u2013620","journal-title":"Synapse"},{"key":"2514_CR42","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cellsig.2010.03.019","volume":"22","author":"AM Polter","year":"2010","unstructured":"Polter AM, Li X (2010) 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal 22:1406\u20131412","journal-title":"Cell Signal"},{"key":"2514_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/syn.20195","volume":"58","author":"T Antonelli","year":"2005","unstructured":"Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L (2005) Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58:193\u2013199","journal-title":"Synapse"},{"key":"2514_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00001756-200505120-00009","volume":"16","author":"LJ Mignon","year":"2005","unstructured":"Mignon LJ, Wolf WA (2005) 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson\u2019s disease. Neuroreport 16:699\u2013703","journal-title":"Neuroreport"},{"key":"2514_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","volume":"229","author":"KB Dupre","year":"2011","unstructured":"Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 229:288\u2013299","journal-title":"Exp Neurol"},{"key":"2514_CR46","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.neuropharm.2011.05.021","volume":"61","author":"CY Ostock","year":"2011","unstructured":"Ostock CY, Dupre KB, Jaunarajs KL, Walters H, George J, Krolewski D, Walker PD, Bishop C (2011) Role of the primary motor cortex in l-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 61:753\u2013760","journal-title":"Neuropharmacology"},{"key":"2514_CR47","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","volume":"27","author":"P Celada","year":"2013","unstructured":"Celada P, Bortolozzi A, Artigas F (2013) Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27:703\u2013716","journal-title":"CNS Drugs"},{"key":"2514_CR48","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","volume":"14","author":"N Santana","year":"2004","unstructured":"Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F (2004) Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100\u20131109","journal-title":"Cereb Cortex"},{"key":"2514_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.expneurol.2018.01.010","volume":"302","author":"I Brys","year":"2018","unstructured":"Brys I, Halje P, Scheffer-Teixeira R, Varney M, Newman-Tancredi A, Petersson P (2018) Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT1A receptor biased agonists. Exp Neurol 302:155\u2013168","journal-title":"Exp Neurol"},{"key":"2514_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00213-008-1452-9","volume":"204","author":"C Marin","year":"2009","unstructured":"Marin C, Aguilar E, Rodriguez-Oroz MC, Bartoszyk GD, Obeso JA (2009) Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology 204:241\u2013250","journal-title":"Psychopharmacology"},{"key":"2514_CR51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1146\/annurev-neuro-071013-013916","volume":"37","author":"AB Nelson","year":"2014","unstructured":"Nelson AB, Kreitzer AC (2014) Reassessing models of basal ganglia function and dysfunction. Annu Rev Neurosci 37:117\u2013135","journal-title":"Annu Rev Neurosci"},{"key":"2514_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.wnf.0000177642.89888.85","volume":"28","author":"GK Isbister","year":"2005","unstructured":"Isbister GK, Buckley NA (2005) The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 28:205\u2013214","journal-title":"Clin Neuropharmacol"},{"key":"2514_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1749-6632.1990.tb16886.x","volume":"600","author":"AR Green","year":"1990","unstructured":"Green AR, Backus LI (1990) Animal models of serotonin behavior. Ann N Y Acad Sci 600:237\u2013248 discussion 248 \u2013 239","journal-title":"Ann N Y Acad Sci"},{"key":"2514_CR54","first-page":"309","volume":"62","author":"D Bijl","year":"2004","unstructured":"Bijl D (2004) The serotonin syndrome. Neth J Med 62:309\u2013313","journal-title":"Neth J Med"},{"key":"2514_CR55","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1021\/jm00140a002","volume":"24","author":"LE Arvidsson","year":"1981","unstructured":"Arvidsson LE, Hacksell U, Nilsson JL, Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikstrom H (1981) 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem 24:921\u2013923","journal-title":"J Med Chem"},{"key":"2514_CR56","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0014-2999(84)90714-3","volume":"106","author":"MD Tricklebank","year":"1984","unstructured":"Tricklebank MD, Forler C, Fozard JR (1984) The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106:271\u2013282","journal-title":"Eur J Pharmacol"},{"key":"2514_CR57","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1017\/S1461145709991222","volume":"13","author":"MB Assie","year":"2010","unstructured":"Assie MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortere R, Koek W, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A (2010) F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol 13:1285\u20131298","journal-title":"Int J Neuropsychopharmacol"},{"key":"2514_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0014-2999(94)90728-5","volume":"263","author":"HH Berendsen","year":"1994","unstructured":"Berendsen HH, Bourgondien FG, Broekkamp CL (1994) Role of dorsal and median raphe nuclei in lower lip retraction in rats. Eur J Pharmacol 263:315\u2013318","journal-title":"Eur J Pharmacol"},{"key":"2514_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0014-2999(91)90150-O","volume":"193","author":"GA Higgins","year":"1991","unstructured":"Higgins GA, Elliott PJ (1991) Differential behavioural activation following intra-raphe infusion of 5-HT1A receptor agonists. Eur J Pharmacol 193:351\u2013356","journal-title":"Eur J Pharmacol"},{"key":"2514_CR60","unstructured":"Assi\u00e9 M-B, Ravailhe V, Benas C, Newman-Tancredi A (2008) Differential effects of 5-HT1A receptor agonists on extracellular levels of 5-HT in hippocampus and of dopamine in frontal cortex of freely moving rats. In: British Association for Psychopharmacology Summer Meeting. Harrogate, Poster ID 59"},{"key":"2514_CR61","doi-asserted-by":"publisher","first-page":"26633","DOI":"10.1038\/srep26633","volume":"6","author":"G Becker","year":"2016","unstructured":"Becker G, Bolbos R, Costes N, Redoute J, Newman-Tancredi A, Zimmer L (2016) Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study. Sci Rep 6:26633","journal-title":"Sci Rep"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-018-2514-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-018-2514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-018-2514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T20:22:08Z","timestamp":1553286128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-018-2514-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2514"],"URL":"https:\/\/doi.org\/10.1007\/s11064-018-2514-y","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Adrian Newman-Tancredi and Mark A. Varney are employees of Neurolixis Inc. At the time the studies were conducted, Andrew C. McCreary was an employee of Brain OnLine B.V.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}